Cargando…
Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the leading causes of hepatocellular carcinoma (HCC) worldwide. Limited data exist on surgical outcomes for NAFLD/NASH-related HCC compared with other HCC etiologies. We evaluated differences in clinic...
Autores principales: | Pal Chaudhary, Surendra, Reyes, Stephanie, Chase, Matthew L, Govindan, Aparna, Zhao, Lei, Luther, Jay, Bhan, Irun, Bethea, Emily, Franses, Joseph W, Paige Walsh, Elizabeth, Anne Dageford, Leigh, Kimura, Shoko, Elias, Nahel, Yeh, Heidi, Markman, James, Bozorgzadeh, Adel, Tanabe, Kenneth, Ferrone, Cristina, Zhu, Andrew X, Andersson, Karin, Thiim, Michael, Antonio Catalano, Onofrio, Kambadakone, Avinash, Vagefi, Parsia A, Qadan, Motaz, Pratt, Daniel, Hashemi, Nikroo, Corey, Kathleen E, Misdraji, Joseph, Goyal, Lipika, Clark, Jeffrey W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078904/ https://www.ncbi.nlm.nih.gov/pubmed/36763374 http://dx.doi.org/10.1093/oncolo/oyac251 |
Ejemplares similares
-
The unmet need of personalized HCC screening—Lessons learned from the Swedish nationwide registries
por: Gairing, Simon Johannes, et al.
Publicado: (2022) -
A new proposal for secondary surveillance following potentially curative therapy of HCC: alternating MRI and CEUS
por: Bansal, Sanjay, et al.
Publicado: (2021) -
The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021) -
Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis
por: Chen, Jifan, et al.
Publicado: (2020) -
CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
por: Colagrande, S., et al.
Publicado: (2020)